About Ducentis BioTheapeutics
Ducentis BioTheapeutics is a company based in Witney (United Kingdom) founded in 2015 was acquired by Arcutis in September 2022. Ducentis BioTheapeutics has raised $2.29 million across 5 funding rounds from investors including Arcutis, Oxford Technology and LifeArc. The company has 6 employees as of October 31, 2021. Ducentis BioTheapeutics operates in a competitive market with competitors including BeiGene, Biogen, Moderna, UCB and Incyte, among others.
- Headquarter Witney, United Kingdom
- Employees 6 as on 31 Oct, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Ducentis Biotherapeutics Ltd.
- Date of Incorporation 12 Nov, 2014
- Jurisdiction 10 TEMPLE BACK, BRISTOL, UNITED KINGDOM
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ducentis BioTheapeutics
Ducentis BioTheapeutics has successfully raised a total of $2.29M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $1.9 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ducentis BioTheapeutics
Ducentis BioTheapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Arcutis, Oxford Technology and LifeArc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage micro-VC investments are focused on UK companies.
|
Locked | Locked | Locked | |
|
Medical research and treatments are supported by the community foundation.
|
Locked | Locked | Locked | |
|
Immunotherapeutic solutions for dermatological conditions are developed.
|
Locked | Locked | Locked |
Investor details for Ducentis BioTheapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ducentis BioTheapeutics
Investment portfolio details for Ducentis BioTheapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ducentis BioTheapeutics
Detailed financials for Ducentis BioTheapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ducentis Biotheapeutics Comparisons
Peer comparison for Ducentis BioTheapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ducentis BioTheapeutics
Ducentis BioTheapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biogen, Moderna, UCB and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
Detailed competitors of Ducentis BioTheapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ducentis Biotheapeutics
Complete news archive for Ducentis BioTheapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ducentis BioTheapeutics
Ducentis BioTheapeutics was founded in 2015.
Ducentis BioTheapeutics is headquartered in Witney, United Kingdom. It is registered at Witney, Oxfordshire, United Kingdom.
Ducentis BioTheapeutics is a funded company, having raised a total of $2.29M across 5 funding rounds to date.
As of Oct 31, 2021, the latest employee count at Ducentis BioTheapeutics is 6.
Founded in 2015, Ducentis BioTheapeutics operates as a UK-based preclinical biotech firm in Witney, focusing on therapeutics for inflammatory and auto-immune conditions. An existing protein is modified to enhance its immunoregulatory role, targeting the CD200CD200R pathway to suppress immune responses. A portfolio of CD200 molecules is advanced through collaborations with Prosarix, Syngene, GVK Bio, and KWS BioTest, supported by seed funding from Oxford Technology.
Ducentis BioTheapeutics's top competitors include Moderna, BeiGene and Serum Institute of India.
Ducentis BioTheapeutics has 3 investors. Key investors include Arcutis, Oxford Technology, and LifeArc.